SMC021 for menopause
Per Open Targets, SMC021 is a calcitonin receptor agonist that reached Phase 2 clinical development for menopause.
Hypothesized mechanism
SMC021 acts as a calcitonin receptor agonist, a pathway implicated in bone metabolism relevant to postmenopausal conditions.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 2.3 of 10 overall, a exploratory reading, from a pathway rated exploratory in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Female representation not stated — applicability to women uncertain (flagged for full text). (band F4, ×0.75).
Corroboration
Only a single line of evidence is provided: a database annotation that SMC021 is a calcitonin receptor agonist developed for menopause. No independent mechanistic studies or converging lines are cited.
Rigor
The sole source is an Open Targets database annotation listing clinical stage and mechanism; no experimental model, trial data, or human-relevant outcome study is presented to assess strength or recency.
Specificity
The claim names a defined molecular target (calcitonin receptor) and a specific action (agonist), giving moderate target specificity, but no data quantifying selectivity or off-target effects are provided.
Plausibility
Calcitonin receptor agonism has a plausible link to postmenopausal bone metabolism, and the candidate reached Phase 2 for menopause, but the single annotation does not connect the target to a specific menopausal phenotype or outcome.
Consistency
There is only one claim, so there is no conflict, but neither is there corroborating signal; the lone annotation is internally consistent but cannot demonstrate converging direction.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Per Open Targets (retrieved 2026-06-16), SMC021 is a clinical candidate for menopause (maximum clinical stage PHASE_2); its mechanism of action is Calcitonin receptor agonist on target calcitonin receptor. Open Targets · mechanistic ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →